Workflow
PHARMARON(300759)
icon
Search documents
康龙化成:预计2025年净利润同比下降6%至10%
Jing Ji Guan Cha Wang· 2026-01-14 02:10
经济观察网2026年1月13日,康龙化成(300759)发布2025年度业绩预告,预计2025年净利润16.14亿元 至16.86亿元,同比下降6%至10%;扣除非经常性损益后的净利润15.07亿元至15.62亿元,同比增长36% 至41%。 ...
2025年泰康医疗健康股票发起下跌13% 牛市跌幅两位数
Zhong Guo Jing Ji Wang· 2026-01-13 19:55
Group 1 - The core viewpoint of the news highlights the performance of the TaiKang Medical Health Fund, which saw declines in its two share classes, with Class C down by 13.45% and Class A down by 13.02% in 2025 [2][3] - The top ten holdings of the TaiKang Medical Health Fund in the third quarter of 2025 included companies such as JingTai Holdings, Kanglong Chemical, Fangzhou Jianke, SanSheng Pharmaceutical, Zhaoyan New Drug, Jiuan Medical, Yirui Technology, Lingrui Pharmaceutical, Baipusais, and Bid Medical [2] - The fund manager, Fu Hongzhe, has a background as a senior researcher at China Europe Fund Management Co., and has been with TaiKang since July 2019, becoming the fund manager on March 8, 2022 [2]
上市公司动态 | 浦发银行2025年净利增10.52%;东鹏饮料净利预增30.46%-37.97%;TCL科技营收破千亿,净利预增169%-191%
Sou Hu Cai Jing· 2026-01-13 19:04
Group 1: Shanghai Pudong Development Bank - The bank reported a net profit of 50.017 billion yuan for 2025, an increase of 10.52% year-on-year [1][2] - Total operating income reached 173.964 billion yuan, reflecting a growth of 1.88% compared to the previous year [2] - The bank's total assets exceeded 1 trillion yuan, reaching 1,008.1746 billion yuan, a 6.55% increase from the previous year [3] Group 2: Dongpeng Beverage - Dongpeng Beverage expects a net profit between 4.34 billion and 4.59 billion yuan for 2025, representing a year-on-year growth of 30.46% to 37.97% [4] - The anticipated operating income is projected to be between 20.76 billion and 21.12 billion yuan, indicating a growth of 31.07% to 33.34% [4] Group 3: TCL Technology - TCL Technology forecasts a net profit of 4.21 billion to 4.55 billion yuan for 2025, marking a significant increase of 169% to 191% year-on-year [5][6] - The company expects to surpass 100 billion yuan in operating revenue, with net profit exceeding 8 billion yuan [5] Group 4: Changjiang Electric Power - Changjiang Electric Power reported a net profit of 34.167 billion yuan for 2025, a 5.14% increase year-on-year [8] - The total operating revenue for the year is expected to be 85.882 billion yuan, reflecting a growth of 1.65% [8] Group 5: China Gold - China Gold anticipates a net profit of 286 million to 368 million yuan for 2025, a decrease of 55% to 65% year-on-year [21] - The decline is attributed to market fluctuations and reduced consumer traffic [21] Group 6: LaKala - LaKala expects a net profit between 1.06 billion and 1.2 billion yuan for 2025, representing a growth of 202% to 242% year-on-year [22] - The increase is primarily due to significant investment income from stock holdings [22] Group 7: Baiwei Storage - Baiwei Storage projects a net profit of 850 million to 1 billion yuan for 2025, indicating a year-on-year increase of 427% to 520% [23] - The growth is driven by improved sales and gross margins in the AI sector [23] Group 8: Shengxin Lithium Energy - Shengxin Lithium Energy forecasts a net loss of 600 million to 850 million yuan for 2025, similar to the previous year's loss [24] - The company attributes the loss to industry supply-demand dynamics and increased exchange losses [24] Group 9: Zhongguancun Online - Zhongguancun Online expects a net loss of 580 million to 700 million yuan for 2025, a significant increase from the previous year's loss of 243 million yuan [25] - The losses are linked to increased promotional investments in overseas markets [25] Group 10: Huaxia Happiness - Huaxia Happiness anticipates a net loss of 16 billion to 24 billion yuan for 2025, a substantial increase from the previous year's loss of 4.817 billion yuan [26] - The decline is due to reduced project turnover and high financial costs [26]
东鹏饮料预计2025年净利润同比增超30%;*ST立方可能因股价低于面值或重大违法被终止上市;联检科技拟收购中鼎检测55%股权|公告精选
Mei Ri Jing Ji Xin Wen· 2026-01-13 15:10
Mergers and Acquisitions - Lianjian Technology plans to acquire 55% equity of Zhongding Testing for 101 million yuan, making it a subsidiary included in the consolidated financial statements after the transaction [1] Termination of Asset Purchase - Yaxing Chemical announced the termination of its plan to issue shares and pay cash for the acquisition of 100% equity of Shandong Tianyi Chemical, which was expected to constitute a major asset restructuring [2] Earnings Disclosure - Kanglong Chemical expects a net profit of 1.614 billion to 1.686 billion yuan for 2025, a year-on-year decrease of 6% to 10%, while revenue is projected to grow by 13% to 16% [3] - Yongyou Network anticipates a net loss of 1.3 billion to 1.39 billion yuan for 2025, reducing losses by 671 million to 761 million yuan year-on-year [4] - Dongpeng Beverage expects a net profit of 4.34 billion to 4.59 billion yuan for 2025, an increase of 1.013 billion to 1.263 billion yuan, representing a growth of 30.46% to 37.97% [5] - Pudong Development Bank forecasts a net profit of 50.017 billion yuan for 2025, a year-on-year increase of 10.52%, with revenue expected to be 173.964 billion yuan, up 1.88% [6] Shareholding Changes - Zhang Yijie, a shareholder of Jixin Technology, plans to reduce holdings by up to 969,030 shares, not exceeding 1% of the total share capital, for personal financial needs [8] - Quantum Leap, a shareholder of Zhangyue Technology, intends to reduce its stake by up to 438,900 shares, not exceeding 1% of the total share capital, due to personal needs [7] - Alibaba Health, a major shareholder of Shuyupingmin, plans to reduce its holdings by up to 810,720 shares, accounting for 2% of the total share capital, for personal financial needs [9] - Anyang Qixu, a shareholder of Xiangyu Medical, intends to reduce its stake by up to 480,000 shares, not exceeding 3% of the total share capital, due to personal financial needs [10] Risk Matters - *ST Lifang announced that its stock price has fallen below 1 yuan, which may lead to delisting due to the stock price being below par value, and it has received a notice of administrative penalty for false records in annual reports from 2021 to 2023 [11]
康龙化成:2025年年度业绩预告
Zheng Quan Ri Bao· 2026-01-13 14:23
(文章来源:证券日报) 证券日报网讯 1月13日,康龙化成发布公告称,公司预计2025年营业收入1387162.56万元至1423989.89 万元,同比增长13%至16%;归属于上市公司股东的净利润161401.57万元至168574.98万元,同比下降 6%至10%。 ...
康龙化成(03759.HK):预计年度净利润相比上年同期下降6%-10%
Ge Long Hui· 2026-01-13 12:52
格隆汇1月13日丨康龙化成(03759.HK)公告,2025年,公司预计营业收入同比增长13%-16%、归属于上 市公司股东的扣除非经常性损益后的净利润同比增长36%-41%、经调整的非《国际财务报告准则》下归 属于上市公司股东的净利润同比增长10%-15%。在主营业务持续向好的情形下,主要由于非经常性损益 的下降,公司归属于上市公司股东的净利润相比上年同期下降6%-10%。 ...
康龙化成:全年净利润变动初步数据-6%至-10%。
Xin Lang Cai Jing· 2026-01-13 12:49
康龙化成:全年净利润变动初步数据-6%至-10%。 ...
康龙化成:全年净利润初步数据16.1亿元人民币至16.9亿元人民币。
Xin Lang Cai Jing· 2026-01-13 12:49
康龙化成:全年净利润初步数据16.1亿元人民币至16.9亿元人民币。 ...
康龙化成发预减,预计2025年归母净利润16.14亿元至16.86亿元 同比下降6%–10%
Zhi Tong Cai Jing· 2026-01-13 12:48
康龙化成(300759)(300759.SZ)发布2025年年度业绩预告,预计2025年度归属于上市公司股东的净利 润16.14亿元至16.86亿元,同比下降6%–10%。 经公司初步测算,2025年度归属于上市公司股东的非经常性损益约为人民币11,000万元至人民币13,000 万元,主要包括计入当期损益的政府补助、其他非流动金融资产公允价值变动收益及投资的中低风险银 行理财产品相关损益等。 ...
康龙化成预期2025年经调整归母净利同比增长10%-15%
Zhi Tong Cai Jing· 2026-01-13 12:48
Core Viewpoint - The company, Kanglong Chemical (300759), anticipates a revenue of approximately 13.872 to 14.24 billion yuan for 2025, representing a year-on-year growth of 13% to 16% [1] Financial Performance Summary - The net profit attributable to shareholders is expected to be around 1.614 to 1.686 billion yuan, reflecting a year-on-year decline of 6% to 10% [1] - The non-recurring net profit is projected to be approximately 1.507 to 1.562 billion yuan, indicating a year-on-year increase of 36% to 41% [1] - The adjusted net profit under non-IFRS standards is estimated to be about 1.7675 to 1.848 billion yuan, showing a year-on-year growth of 10% to 15% [1] Q4 2025 Performance Expectations - For the fourth quarter of 2025, the company forecasts a revenue growth of 14.79% year-on-year [1] - The net profit attributable to shareholders, excluding non-recurring items, is expected to increase by 54.09% year-on-year [1] - The adjusted net profit under non-IFRS standards is projected to grow by 16.36% year-on-year [1]